LoginSignup
Imagen de perfil
SemiGrowth
@SemiGrowth
1Año·

$MEDP (-3,88 %) Were earnings really that bad? Sales are supposed to be lower, but the bottom line has been raised considerably and the backlog has also grown.

Billings have collapsed, which is probably the reason, but I see a good long-term entry point

2
17 Comentarios
Imagen de perfil
Tenbagger2024@Tenbagger2024
1Año
As far as I know, there are figures on Wednesday.
It is often the case that some investors sell before the figures and get nervous.
Let's wait and see on Wednesday.
At the moment I think the whole market is pretty nervous.
•
2
•
Ver todas las 3 respuestas adicionales
Imagen de perfil
Brody@Brody
1Año
@Tenbagger2024 Do you have an idea? Sell on good news? At first glance, it can't be the figures.
••
Imagen de perfil
Brody@Brody
1Año
••
Usuario eliminado
1Año
Comentario eliminado
Imagen de perfil
SemiGrowth@SemiGrowth
1Año
@Memo0606 am now in for the long term. I don't think the valuation is too high. MEDP is virtually a shovel manufacturer in an important sector of the future
••
Usuario eliminado
1Año
Comentario eliminado
Imagen de perfil
SemiGrowth@SemiGrowth
1Año
@Memo0606 I've just added it to my watchlist, but haven't gotten around to it yet
••
Usuario eliminado
1Año
Comentario eliminado
Imagen de perfil
SemiGrowth@SemiGrowth
1Año
@Memo0606 I just had a look at it, it looks great. I think I'll go in there sometime
••
Usuario eliminado
1Año
Comentario eliminado
Imagen de perfil
SemiGrowth@SemiGrowth
1Año
@Memo0606 fantastic margins (80 Gross, >30 Net, >20 FCF), favorable in historical comparison. The product positioning in the high-margin segments (animals, cancer) and especially the latter is likely to be a growth market. At the moment, everyone is only looking at Eli Lilly, which is why this could be an anti-cyclical play in the sector. I like how the management handles cash (conservative). Only the relatively high level of debt is a negative point. Sales growth is currently low. But profit and FCF growth is extremely high (due to base effects). The valuation of 13 P/E is quite favorable in my opinion. Oh and Merck is also a long-term runner, compounder or quality stock with a discount
••
Usuario eliminado
1Año
Comentario eliminado
Imagen de perfil
SemiGrowth@SemiGrowth
1Año
@Memo0606 I will probably go in in installments, but I don't know when yet.

You can consider a momentum discount strategy against the "runaway". For example, you buy when it rises/falls above 108 or below 101. Then you either have a low price and if it doesn't fall that low, you're still in. Or you go in in very small tranches. Then you at least have a few shares should it run away from you
•
1
•
Ver una respuesta más
Únase a la conversación
InscríbaseInicio de sesión